Nirsevimab is set to become the second RSV prophylactic on the market for infants and offers several advantages over its first-to-market competition, but Pfizer’s vaccine rival is fast approaching.

Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.

Facing an unprecedented downturn, Chinese biopharma companies cannot be self-reliant to go global, investors say during a Hong Kong Biotech Summit.

Pfizer’s bivalent vaccine candidate showed efficacy in RSV patients with multiple respiratory infection symptoms and may offer protection against the A and B strains of the virus.